Literature DB >> 19215796

BCR/ABL rearrangement with b3a3 fusion transcript in a case of childhood acute lymphoblastic leukemia.

Juwon Kim1, Tae Sung Park, Chuhl Joo Lyu, Jaewoo Song, Kyung-A Lee, Sue Jung Kim, Hyeon-Ji Lee, Jong Rak Choi.   

Abstract

The role of BCR/ABL isoforms and their relationship to leukemia phenotype have been of major concern. Atypical BCR/ABL mRNA transcripts lacking exon a2 have been reported in 12 cases of acute lymphoblastic leukemia (ALL) to date; among them, a b3a3 type transcript has been reported only once in the childhood ALL. Reported here is the case of a patient with Philadelphia-positive (Ph(+)) ALL expressing a b3a3 type transcript, a rare type of BCR/ABL mRNA lacking ABL exon a2 sequences. Bone marrow showed a hypercellular marrow with leukemic blasts positive for CD10, CD19, CD79a, and cytoplasmic mu, which is consistent with pre-B ALL. The G-banding and fluorescence in situ hybridization analyses indicated Ph(+). After the patient was diagnosed with ALL-L2, induction chemotherapy was performed and imatinib mesylate was thereafter given as the maintenance therapy. Sequencing analysis showed deletion of ABL a2 in the polymerase chain reaction product, which corresponded to a b3a3 fusion transcript. To our knowledge, this is the second report of an aberrant BCR/ABL product lacking ABL exon a2 in childhood ALL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19215796     DOI: 10.1016/j.cancergencyto.2008.11.006

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  4 in total

1.  A rare e14a3 BCR/ABL fusion transcript in acute lymphoblastic leukemia patient treated with CAR-modified T-cell therapy.

Authors:  Haodong Cai; Li Yang; Kefeng Shen; Wei Zhang; Jie Xiong; Meilan Zhang; Xia Mao; Ying Wang; Min Xiao
Journal:  Oncol Lett       Date:  2017-12-13       Impact factor: 2.967

2.  A novel BCR-ABL1 fusion gene identified by next-generation sequencing in chronic myeloid leukemia.

Authors:  Xiaodong Lyu; Jingke Yang; Xianwei Wang; Jieying Hu; Bing Liu; Yu Zhao; Zhen Guo; Bingshan Liu; Ruihua Fan; Yongping Song
Journal:  Mol Cytogenet       Date:  2016-06-27       Impact factor: 2.009

3.  The bioengineered HALOA complex induces anoikis in chronic myeloid leukemia cells by targeting the BCR-ABL/Notch/Ikaros/Redox/Inflammation axis.

Authors:  Vivek Singh; Ranjana Singh; Abbas Ali Mahdi; Anil Kumar Tripathi
Journal:  J Med Life       Date:  2022-05

4.  A novel dic (17;18) (p13.1;q11.2) with loss of TP53 and BCR/ABL rearrangement in an Imatinib resistant chronic myeloid leukemia.

Authors:  Walid Al-Achkar; Abdulsamad Wafa; Faten Moassass; Moneeb Abdullah Kassem Othman
Journal:  Mol Cytogenet       Date:  2012-08-20       Impact factor: 2.009

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.